基因工程人干扰素α-1滴眼剂治疗和预防急性出血性结膜炎——1988年北京流行期间的临床研究

Recombinant Human Interferonα-1(rHuIFNα-1) Eyedrops in Treatment and Prophylaxis of Acute Hemorrhagic Conjunctivitis:The Clinical Investigations During the 1988 Outbreak in Beijng

用基因工程人干扰素α-1(rHuIFNα-1)和无环乌苷(ACV)滴眼剂随机双盲法治疗63例(126眼)AHC 患者。两组在治愈及好转时间方面无显著差异。对19例AHC 重症病例在用其它药物治疗无效后改用rHuIFNα-1治疗,治愈或明显缓解。另51例与患者密切接触的家属双盲法用rHuIFNα-1或ACV 预防用药后,rHuIFNα-1组发病率明显低于ACV 组,两组差异非常显著(P<0.01),认为rHuIFNα-1可在AHC流行期问用于预防和治疗重症病例。

Randomized double blind studies of rHuIFN-αl and ACV eyedrops for treatment of63 cases (126 eyes) of acute hemorrhagic conjunctivitis (AHC) revealed that there wereno significant differences in the time required for cure or improvement between bothgroups.19 severe cases that had been refractory to other drugs were cured or improvedby resorting to topical rHuIFNα-1.51 family members in close contact with the patientswere given rHuIFNα-1 or ACV eyedrops for prophylaxis double blindly as two separategroups,with the result that the incidence of AHC was significantly lower in the formergroup.(P<0.01).The authors are of the opinion that rHuIFNα-1 might be useful inprophylaxis of AHC and treatment of severe cases during an outbreak of the disease.